Clinton Group’s Impax Laboratories, Inc. IPXL Stock Holding History

Clinton Group’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-40,404	Closed	-$535K	–	1116
2016 Q4	$535K	Buy	40,404 +2,764	+7%	+$47.3K	0.03%	558
2016 Q3	$892K	Buy	+37,640	New	+$1.01M	0.04%	530
2016 Q2	–	Sell	-6,466	Closed	-$207K	–	1117
2016 Q1	$207K	Buy	+6,466	New	+$227K	0.01%	812

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Clinton Group's IPXL Position: Q1 2017 in Review

Clinton Group sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 40,404 shares — an estimated $535K sold.

Clinton Group first reported a position in IPXL in Q1 2016 and held it in 3 quarters. The position peaked at $892K in Q3 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

Clinton Group reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
Clinton Group sold 40,404 Impax Laboratories, Inc. shares in Q1 2017, an estimated $535K.
Clinton Group first reported a position in Impax Laboratories, Inc. in Q1 2016 and held it in 3 quarters.
Clinton Group's Impax Laboratories, Inc. position peaked at $892K in Q3 2016.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Clinton Group's 13F filing for Q1 2017, filed 10 May 2017.